Top Markets
Coin of the day
Ovoca Bio plc Ovoca Bio plc

Ovoca Bio plc

OVB
Rank in Stocks #99999
Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the... Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. It also engages in mineral exploration, as well as provides support services. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.
Share Price
$0.09933121
Market Cap
$29.15K
Change (1 day)
0.57%
Change (1 year)
449.49%
Country
IE
Trade Ovoca Bio plc (OVB)

Category

P/E ratio for Ovoca Bio plc (OVB)
P/E ratio as of March 2026 TTM: -0.17
According to Ovoca Bio plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.17. At the end of 2022 the company had a P/E ratio of -0.87.
P/E ratio history for Ovoca Bio plc from 2001 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.17 4.81%
2023 -0.16 -81.69%
2022 -0.87 -60.98%
2021 -2.23 -32.63%
2020 -3.32 -46.38%
2019 -6.19 70.18%
2018 -3.64 -79.54%
2017 -17.77 61.95%
2016 -10.97 273.62%
2015 -2.94 162.78%
2014 -1.12 110.57%
2013 -0.53 -92.03%
2012 -6.66 -215.31%
2011 5.77 -149.89%
2010 -11.57 -213.67%
2009 10.18 -1,056.15%
2008 -1.06 -98.56%
2007 -73.98 894.57%
2006 -7.44 -56.91%
2005 -17.26 -5.58%
2004 -18.28 31.42%
2003 -13.91 -55.68%
2002 -31.39 -2.04%
2001 -32.04 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
10.72 -6,490.64%
DK
30.14 -18,074.96%
US
17.03 -10,257.84%
US
30.44 -18,250.57%
BE
38.30 -22,939.53%
NL
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.